Randomized Trialhigh evidence

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·December 6, 2025·PMID 41207310

Why it matters

Amylin receptor agonists represent a novel mechanism for obesity pharmacotherapy. Eloralintide’s substantial weight loss in a phase 2 trial suggests it could become an important option, especially for patients who do not tolerate or respond adequately to GLP-1-based treatments.

Infographic summary of Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled